- Home
- CNR vs SLNO Comparison
CNR vs SLNO Comparison
Compare CNR & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- SLNO
- Stock Information
- Founded
- CNR 1864
- SLNO 1999
- Country
- CNR United States
- SLNO United States
- Employees
- CNR N/A
- SLNO N/A
- Industry
- CNR Coal Mining
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CNR Energy
- SLNO Health Care
- Exchange
- CNR Nasdaq
- SLNO Nasdaq
- Market Cap
- CNR 4.4B
- SLNO 3.8B
- IPO Year
- CNR N/A
- SLNO 2014
- Fundamental
- Price
- CNR $83.48
- SLNO $64.20
- Analyst Decision
- CNR Strong Buy
- SLNO Strong Buy
- Analyst Count
- CNR 5
- SLNO 9
- Target Price
- CNR $110.10
- SLNO $116.78
- AVG Volume (30 Days)
- CNR 1.1M
- SLNO 1.4M
- Earning Date
- CNR 11-06-2025
- SLNO 11-04-2025
- Dividend Yield
- CNR 0.48%
- SLNO N/A
- EPS Growth
- CNR N/A
- SLNO N/A
- EPS
- CNR 0.51
- SLNO N/A
- Revenue
- CNR $3,275,589,000.00
- SLNO $32,656,999.00
- Revenue This Year
- CNR $93.87
- SLNO N/A
- Revenue Next Year
- CNR $8.40
- SLNO $182.29
- P/E Ratio
- CNR $163.00
- SLNO N/A
- Revenue Growth
- CNR 47.13
- SLNO N/A
- 52 Week Low
- CNR $58.19
- SLNO $41.50
- 52 Week High
- CNR $134.59
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- CNR 44.73
- SLNO 48.91
- Support Level
- CNR $82.39
- SLNO $64.30
- Resistance Level
- CNR $93.07
- SLNO $67.93
- Average True Range (ATR)
- CNR 4.90
- SLNO 3.52
- MACD
- CNR -1.94
- SLNO 0.33
- Stochastic Oscillator
- CNR 5.31
- SLNO 34.24
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.